← Back to headlines
Moderna Stock Soars 179% on Melanoma Therapy Candidate Success
Moderna's stock has surged by 179% following positive developments regarding its melanoma therapy candidate, which is seen as rewriting the company's growth story.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
XPeng Stock Falls After Q2 Earnings Miss, Robotics Arm Raises $900M
24m ago
Nvidia Manager Indicted in Taiwan for AI Chip Smuggling
25m ago
ADNOC Awards McDermott $1 Billion-Plus Contract for Offshore Gas Project
26m ago
Three Cracks in Consumer Spending Reveal Why Walmart Had Its Worst Day Since 2022 Despite an Earnings Beat
29m ago